Checkpoint inhibition in meningiomas

Immunotherapy

Volumn 8, Issue 6, 2016, Pages 721-731

  Bi, Wenya Linda ^a   Wu, Winona W ^a   Santagata, Sandro ^a   Reardon, David A ^b   Dunn, Ian F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

checkpoint inhibition; immunotherapy; meningioma; PD 1; PD L1; targeted pharmacotherapy

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; T LYMPHOCYTE RECEPTOR;

ADJUVANT RADIOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MENINGIOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR ESCAPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; MENINGIOMA;

EID: 84971275543     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0017     Document Type: Review

References (79)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002).
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
4. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12(4), 298-306 (2012).
5. Taube JM, Anders RA, Young GD et al. Colocalization of infammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4(127), 127ra137 (2012).
6. Liu Y, Carlsson R, Ambjorn M et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J. Neurosci. 33(35), 14231-14245 (2013).
7. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
8. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480 (7378), 480-489 (2011).
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Can. 12(4), 252-264 (2012).
10. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical beneft in melanoma patients. Clin. Cancer Res. 19(19), 5300-5309 (2013).
11. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 341(6151), 1192-1198 (2013).
12. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
13. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
14. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl. J. Med. 366(26), 2455-2465 (2012).
15. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015).
16. Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257), 207-211 (2015).
17. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl. J. Med. 369(2), 134-144 (2013).
18. Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523(7560), 337-341 (2015).
19. Hodi FS, Oble DA, Drappatz J et al. CTLA-4 blockade with ipilimumab induces signifcant clinical beneft in a female with melanoma metastases to the CNS. Nat. Clin. Pract. Oncol. 5(9), 557-561 (2008).
20. Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase 2 trial. Lancet Oncol 13(5), 459-465 (2012).
21. Muller C, Holtschmidt J, Auer M et al. Hematogenous dissemination of glioblastoma multiforme. Sci. Transl. Med. 6(247), 247ra101 (2014).
22. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin. Cancer Res. 19(12), 3165-3175 (2013).
23. Berghoff AS, Kiesel B, Widhalm G et al. Programmed death ligand 1 expression and tumor-infltrating lymphocytes in glioblastoma. Neuro Oncol. 17(8), 1064-1075 (2015).
24. Vlahovic G, Fecci PE, Reardon D, Sampson JH. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro Oncol. 17(8), 1043-1045 (2015).
25. Reardon DA, Freeman G, Wu C et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 16(11), 1441-1458 (2014).
26. Avril T, Saikali S, Vauleon E et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specifc T cell functions. J. Neuroimmunol. 225(1-2), 22-33 (2010).
27. Wilmotte R, Burkhardt K, Kindler V et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 16(10), 1081-1085 (2005).
28. Wintterle S, Schreiner B, Mitsdoerffer M et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63(21), 7462-7467 (2003).
29. Doucette T, Rao G, Rao A et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol. Res. 1(2), 112-122 (2013).
30. Fecci PE, Ochiai H, Mitchell DA et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4 + T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13(7), 2158-2167 (2007).
31. Zeng J, See AP, Phallen J et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86(2), 343-349 (2013).
32. Belcaid Z, Phallen JA, Zeng J et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specifc memory response in a murine glioma model. PloS ONE 9(7), e101764 (2014).
33. Reardon DA, Gokhale PC, Klein SR et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res. 4(2), 124-135 (2016).
34. Castellano F, Ruggiero G. Meningiomas of the posterior fossa. Acta Radiol. Suppl. 104, 1-177 (1953).
35. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M et al. Identifcation of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 30(20), 2333-2344 (2011).
36. Louis DN, Ohgaki H, Wiestler OD et al. WHO Classifcation of Tumours of the Central Nervous System (4th Edition).IARC Press, Lyon, France (2007).
37. Pearson BE, Markert JM, Fisher WS et al. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg. Focus 24(5), E3 (2008).
38. Tanzler E, Morris CG, Kirwan JM, Amdur RJ, Mendenhall WM. Outcomes of WHO Grade I meningiomas receiving defnitive or postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 79(2), 508-513 (2011).
39. Van Alkemade H, De Leau M, Dieleman EM et al. Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol. 14(5), 658-666 (2012).
40. Rogers L, Barani I, Chamberlain M et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J. Neurosurg. 122(1), 4-23 (2015).
41. Perry A, Louis DN, Scheithauer BW et al. Meningiomas. In: WHO Classifcation of Tumours of the Central Nervous System.Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). IARC, Lyon, France 164-172 (2007).
42. Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J. Neurosurg. 86(5), 793-800 (1997).
43. Durand A, Labrousse F, Jouvet A et al. WHO grade II and III meningiomas: a study of prognostic factors. J. Neuroonc. 95(3), 367-375 (2009).
44. Sun SQ, Kim AH, Cai C et al. Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 75(4), 347-354 (2014).
45. Sun SQ, Cai C, Murphy RK et al. Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurgery 75(4), 356-363 (2014).
46. Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. Neurosurg. Focus 2(4), e3 (1997).
47. Rouleau GA, Merel P, Lutchman M et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fbromatosis type 2. Nature 363(6429), 515-521 (1993).
48. Fontaine B, Rouleau GA, Seizinger BR et al. Molecular genetics of neurofbromatosis 2 and related tumors (acoustic neuroma and meningioma). Ann. NY Acad. Sci. 615, 338-343 (1991).
49. Ruttledge MH, Sarrazin J, Rangaratnam S et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat. Genet. 6(2), 180-184 (1994).
50. Clark VE, Erson-Omay EZ, Serin A et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123), 1077-1080 (2013).
51. Brastianos PK, Horowitz PM, Santagata S et al. Genomic sequencing of meningiomas identifes oncogenic SMO and AKT1 mutations. Nat. Genet. 45(3), 285-289 (2013).
52. Kalamarides M, Niwa-Kawakita M, Leblois H et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 16(9), 1060-1065 (2002).
53. Abedalthagaf M, Bi WL, Aizer AA et al. Oncogenic PI3Kinase mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. doi: 10.1093/neuonc/nov316 (2016) (Epub ahead of print).
54. Bi WL, Abedalthagaf M, Horowitz P et al. Genomic landscape of intracranial meningiomas. J. Neurosurg.doi:10.3171/2015.6JNS15591 (2016) (Epub ahead of print).
55. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1), 22-39 (1957).
56. Aizer AA, Abedalthagaf M, Bi WL et al. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 18(2), 269-74 (2016).
57. Domingues PH, Sousa P, Otero A et al. Proposal for a new risk stratifcation classifcation for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol. 16(5), 735-747 (2014).
58. Kaley T, Barani I, Chamberlain M et al. Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: a RANO review. Neuro Oncol. 16(6), 829-840 (2014).
59. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J. Neuroonc. 99(3), 365-378 (2010).
60. Furtner J, Schopf V, Seystahl K et al. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro Oncol. 18(3), 401-407 (2015).
61. Rossi ML, Cruz Sanchez F, Hughes JT, Esiri MM, Coakham HB. Immunocytochemical study of the cellular immune response in meningiomas. J. Clin. Pathol. 41(3), 314-319 (1988).
62. Becker I, Roggendorf W. Immunohistological investigation of mononuclear cell infltrates in meningiomas. Acta Neuropathol. 79(2), 211-216 (1989).
63. Bo L, Mork SJ, Nyland H. An immunohistochemical study of mononuclear cells in meningiomas. Neuropathol. Appl. Neurobiol. 18(6), 548-558 (1992).
64. Asai J, Suzuki R, Fujimoto T et al. Fluorescence automatic cell sorter and immunohistochemical investigation of CD68-positive cells in meningioma. Clin. Neurol. Neurosurg. 101(4), 229-234 (1999).
65. Grund S, Schittenhelm J, Roser F et al. The microglial/macrophagic response at the tumour-brain border of invasive meningiomas. Neuropathol. Appl. Neurobiol. 35(1), 82-88 (2009).
66. Domingues PH, Teodosio C, Ortiz J et al. Immunophenotypic identifcation and characterization of tumor cells and infltrating cell populations in meningiomas. Am. J. Pathol. 181(5), 1749-1761 (2012).
67. Fang L, Lowther DE, Meizlish ML et al. The immune cell infltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol. 15(11), 1479-1490 (2013).
68. Domingues PH, Teodosio C, Otero A et al. Association between infammatory infltrates and isolated monosomy 22/del(22q) in meningiomas. PloS ONE 8(10), e74798 (2013).
69. Du Z, Abedalthagaf M, Aizer AA et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6(7), 4704-4716 (2015).
70. Domingues P, Gonzalez-Tablas M, Otero A et al. Tumor infltrating immune cells in gliomas and meningiomas. Brain Behav. Immun. 53, 1-15 (2016).
71. Han SJ, Reis G, Kohanbash G et al. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Presented at: 20th Society for Neuro-Oncology Annual Meeting. San Antonio, TX, USA, 19-22 November 2015.
72. Sahin U, Koslowski M, Tureci O et al. Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. 6 (10), 3916-3922 (2000).
73. Keller A, Ludwig N, Comtesse N, Hildebrandt A, Meese E, Lenhof HP. A minimally invasive multiple marker approach allows highly effcient detection of meningioma tumors. BMC Bioinformatics 7, 539 (2006).
74. Syed ON, Mandigo CE, Killory BD, Canoll P, Bruce JN. Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J. Clin. Neurosci. 19 (7), 1016-1021 (2012).
75. Baia GS, Caballero OL, Ho JS et al. NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches. Cancer Immunol. Res. 1(5), 296-302 (2013).
76. Harz C, Ludwig N, Lang S et al. Secretion and immunogenicity of the meningioma-associated antigen TXNDC16. J. Immunol. 193(6), 3146-3154 (2014).
77. Caffo M, Caruso G, Germano A, Galatioto S, Meli F, Tomasello F. CD68 and CR3/43 immunohistochemical expression in secretory meningiomas. Neurosurgery 57(3), 551-557 (2005).
78. Andersen BM, Pluhar GE, Seiler CE et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res. 73(10), 2987-2997 (2013).
79. Long DM. Vascular ultrastructure in human meningiomas and schwannomas. J. Neurosurg. 38 (4), 409-419 (1973).